OB3.F OPTIBIOTIX HLTH PLC LS-02
- Market cap
- EUR 5.37M
- P/E
- -
- P/B
- 1.07x
- ROE
- -61.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is OB3.F undervalued?
Graham numberThe Graham number of OPTIBIOTIX HLTH PLC LS-02 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
OPTIBIOTIX HLTH PLC LS-02 fundamental analysis
No fundamental analysis for OPTIBIOTIX HLTH PLC LS-02 yet.
OPTIBIOTIX HLTH PLC LS-02 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About OPTIBIOTIX HLTH PLC LS-02
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential health benefits. Its first-generation products include Slimbiome, which offers …
Full company profileOPTIBIOTIX HLTH PLC LS-02 financial statements
OPTIBIOTIX HLTH PLC LS-02 annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 2.21M | 457K | 644K | 870K | 1.17M |
| Gross Profit | 1.12M | 244K | 320K | 331K | 614K |
| Operating Income | -1.37M | -10.5M | -1.70M | -2.27M | -3.13M |
| EBITDA | - | 2.67M | -1.49M | -2.06M | -2.93M |
| Net Income | 6.26M | 2.59M | -2.04M | -1.81M | -3.89M |
| EPS | 0.07 | 0.03 | -0.02 | -0.02 | -0.04 |
| Balance Sheet | |||||
| Total Assets | 20.1M | 11.5M | 9.40M | 9.05M | 6.89M |
| Total Liabilities | 1.97M | 643K | 532K | 647K | 610K |
| Shareholders' Equity | 18.1M | 10.9M | 8.87M | 8.40M | 6.28M |
| Cash & Short-term Investments | 2.01M | 1.05M | 635K | 739K | 1.04M |
| Cash Flow | |||||
| Operating Cash Flow | -1.57M | -1.11M | -1.53M | -1.77M | -1.77M |
| Capital Expenditure | 194K | 168K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -1.76M | -1.28M | -1.53M | -1.77M | -1.77M |
| Ratios | |||||
| ROE | 34.5% | 23.7% | -23.0% | -21.5% | -61.9% |
| ROA | 31.1% | 22.4% | -21.7% | -20.0% | -56.4% |
| Net Profit Margin | 282.9% | 566.1% | -316.6% | -207.5% | -333.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
OPTIBIOTIX HLTH PLC LS-02 dividends
OPTIBIOTIX HLTH PLC LS-02 has not paid dividends in the last 6 fiscal years.
Who owns OPTIBIOTIX HLTH PLC LS-02
- Insiders 11.35%
- Institutions 7.72%
- Public & others 80.94%
- Shares outstanding 103M
- Free float 92.6M
OPTIBIOTIX HLTH PLC LS-02 company profile
- Company name
- OPTIBIOTIX HLTH PLC LS-02
- Ticker
- OB3.F
- ISIN
- GB00BP0RTP38
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 9
- Fiscal year end
- December
- Address
- Innovation Centre, York, United Kingdom, YO10 5DG
- Website
- optibiotix.com
About OPTIBIOTIX HLTH PLC LS-02
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential health benefits. Its first-generation products include Slimbiome, which offers a scientifically supported, non-pharmaceutical approach to reduce hunger and cravings; and WellBiome a novel in vitro model of the human gut. In addition, the company offers second-generation solutions, including Sweetbiotix which are dietary fibres used as an alternative to sugar and existing sweeteners; and Microbiome Modulators. Further, it provides CholBiome, a food supplement for reducing cholesterol and blood pressure and supporting vascular health; OptiBiotics, a portfolio of prebiotics developed to target and enhance the growth of specific probiotics; and SlimBiome X3, a supplement that helps users cut calories without hunger and cravings. The company was formerly known as Ducat Ventures PLC and changed its name to OptiBiotix Health Plc in August 2014. OptiBiotix Health Plc was incorporated in 2006 and is headquartered in York, the United Kingdom.
OPTIBIOTIX HLTH PLC LS-02 management
4- Mr. Stephen Patrick O'HaraFounder, CEO & Executive Director · born 1960
- Mr. David Jonathan Blain ACACFO, Finance Director, Company Secretary & Director · born 1961
- Dr. Sofia KolydaExecutive Director of Research & Development and Executive Director · born 1973
- Paul CanningsHead of Operations & Quality